Home Neoplasma Ahead of print Neoplasma Vol.66, No.3, p.343-349, 2019

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.66, No.3, p.343-349, 2019

Title: Development of a five-gene signature as a novel prognostic marker in ovarian cancer
Author: R. Wang, X. H. Ye, X. L. Zhao, J. L. Liu, C. Y. Zhang

Abstract: The prognosis of ovarian cancer (OC) remains poor. Thus, the present study aims to identify independent prognostic factor in OC patients. OC gene expression studies GSE26712 and TCGA-OV were included in this study. Prognosis-associated differentially expressed genes (DEGs) between normal ovarian tissue and OC were identified. LASSO Cox proportional hazards regression model was conducted and a prognostic signature was constructed based on these DEGs. The predictive ability of the signature was analyzed in the training set and test set. The prognosis performance of the signature was compared with CA-125 and HE4. Gene set enrichment analysis (GSEA) was conducted to identify relevant mechanism. 332 DEGs were identified, out of which 64 DEGs were significantly correlated with the overall survival (OS) of OC patients, and 5 DEGs (IGF2, PEG3, DCN, LYPD1 and RARRES1) were applied to build a 5-gene signature. Patients in the 5-gene signature low-risk group had significantly better OS compared to those in the 5-gene high-risk group (p=0.0004) in the training set. Similar results were found in the test set, and the signature was also an independent prognostic factor. The prognosis performance of the 5-gene signature was significantly better than that of CA-125 and HE4. GSEA suggested that OC samples in the 5-gene high-risk group were significantly enriched in WNT/β-catenin signaling and epithelial-mesenchymal transition. We developed and validated a 5-gene signature that might be used as an independent prognostic factor in patients with OS.

Keywords: ovarian cancer; prognostic signature; overall survival
Published online: 28-May-2019
Year: 2019, Volume: 66, Issue: 3 Page From: 343, Page To: 349
doi:10.4149/neo_2018_180705N447


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.